AMRX

Amneal tops Q3 estimates as strong Affordable Medicines and Specialty growth drives higher 2026 guidance and boosts its growth outlook.

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript

Amneal Pharmaceuticals NASDAQ: AMRX reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an expected decline at its AvKARE business. Adjusted EBITDA rose 30% to $207 million, while adjusted earnings per share increased 53% to $0.26.

Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.17 per share a year ago.

–  Q3 2026 Net Revenue of $863 million ; GAAP Net Loss of $22 million ; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million ; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full Year Guidance –

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is how Amneal Pharmaceuticals (AMRX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

Investors need to pay close attention to AMRX stock based on the movements in the options market lately.

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.